HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone813-509-2417
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees2
Next Earnings Date8/19/2019 (Estimated)
OptionableNot Optionable
HedgePath Pharmaceuticals (OTCMKTS:HPPI) Frequently Asked Questions
What is HedgePath Pharmaceuticals' stock symbol?
HedgePath Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HPPI."
When is HedgePath Pharmaceuticals' next earnings date?
Has HedgePath Pharmaceuticals been receiving favorable news coverage?
News articles about HPPI stock have trended negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. HedgePath Pharmaceuticals earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for HedgePath Pharmaceuticals.
Who are some of HedgePath Pharmaceuticals' key competitors?
What other stocks do shareholders of HedgePath Pharmaceuticals own?
Who are HedgePath Pharmaceuticals' key executives?
HedgePath Pharmaceuticals' management team includes the folowing people:
- Mr. Nicholas Jon Virca, Pres & CEO (Age 73)
- Mr. Garrison J. Hasara CPA, CPA, CFO, Treasurer, Sec. & Chief Compliance Officer (Age 50)
How do I buy shares of HedgePath Pharmaceuticals?
Shares of HPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is HedgePath Pharmaceuticals' stock price today?
One share of HPPI stock can currently be purchased for approximately $0.0650.
How big of a company is HedgePath Pharmaceuticals?
What is HedgePath Pharmaceuticals' official website?
How can I contact HedgePath Pharmaceuticals?
HedgePath Pharmaceuticals' mailing address is 4830 W. Kennedy Blvd. Suite 600, Tampa FL, 33609. The company can be reached via phone at 813-509-2417 or via email at [email protected]
MarketBeat Community Rating for HedgePath Pharmaceuticals (OTCMKTS HPPI)
MarketBeat's community ratings are surveys of what our community members think about HedgePath Pharmaceuticals and other stocks. Vote "Outperform" if you believe HPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
